iBio (IBIO) Net Cash Flow (2010 - 2026)
iBio (IBIO) posted quarterly Net Cash Flow of $18.9 million for Q1 2026, up 1023.6% year-over-year from $1.7 million in Q1 2025, and up 3240.92% quarter-over-quarter from $567000.0 in Q4 2025.
iBio (IBIO) Net Cash Flow (2010 - 2026) Analysis & Trends
iBio (IBIO) has reported Net Cash Flow for 17 consecutive years, with $18.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow rose 1023.6% year-over-year to $18.9 million; the TTM figure through Mar 2026 stood at $42.7 million (up 3487.46% YoY), while the FY2025 annual figure was -$5.6 million, down 182.22% from the prior year.
- Net Cash Flow grew to $18.9 million in Q1 2026 per IBIO's latest filing, from $567000.0 in the prior quarter.
- Across five years, Net Cash Flow topped out at $19.5 million in Q3 2025 and bottomed at -$12.8 million in Q3 2022.
- Historically, Net Cash Flow has averaged $157352.9 across 5 years, with a median of -$2.1 million in 2025.
- Annual changes were most pronounced in 2024 — Net Cash Flow tumbled 476.18% — and 2026, when it surged 1023.6%.
- iBio's Net Cash Flow stood at -$11.9 million in 2022, then soared by 94.13% to -$701000.0 in 2023, then sank by 476.18% to -$4.0 million in 2024, then surged by 114.04% to $567000.0 in 2025, then soared by 3240.92% to $18.9 million in 2026.
- Business Quant data shows IBIO's Net Cash Flow at $18.9 million in Q1 2026, $567000.0 in Q4 2025, and $19.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | iBio | 172.22 Mn | 172.22 Mn | - | 18.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18.94 Mn |
| Mar 31, 2026 | 18.94 Mn |
| Dec 31, 2025 | 567,000.00 |
| Dec 31, 2025 | 567,000.00 |
| Sep 30, 2025 | 19.55 Mn |
| Sep 30, 2025 | 19.55 Mn |
| Jun 30, 2025 | 3.63 Mn |
| Jun 30, 2025 | 3.63 Mn |
| Mar 31, 2025 | -2.05 Mn |
| Mar 31, 2025 | -2.05 Mn |
| Dec 31, 2024 | -4.04 Mn |
| Dec 31, 2024 | -4.04 Mn |
| Sep 30, 2024 | -3.16 Mn |
| Sep 30, 2024 | -3.16 Mn |
| Jun 30, 2024 | 7.99 Mn |
| Jun 30, 2024 | 7.99 Mn |
| Mar 31, 2024 | 2.37 Mn |
| Mar 31, 2024 | 2.37 Mn |
| Dec 31, 2023 | -701,000.00 |
| Dec 31, 2023 | -701,000.00 |